Related Experiment Video
Updated: Jul 19, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia
Abstract:
Medical therapy with alpha-adrenergic receptor blockers and 5-alpha-reductase inhibitors is currently considered first-line treatment for men with moderate to severe symptoms of benign prostatic hyperplasia (BPH). Given the success that has been realized with monotherapy with each of these agents, interest in combination therapy has grown. Large-scale trials to test the efficacy of such combinations are lacking; however, a few studies, such as the Medical Therapy of Prostatic Symptoms trial, have yielded results indicating that the 2 types of agents combined can reduce the risk of symptomatic progression and acute urinary retention, as well as the need for invasive therapy. More research is needed to clarify the roles of these agents in the treatment of BPH and in the optimization of patient quality of life.
Related Concept Videos
Urinary Tract Calculi III: Medical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Urinary Tract Calculi VI: Surgical Management
